Outpatient medication costs of patients with cystic fibrosis in Germany

Applied Health Economics and Health Policy

Volumn 8, Issue 2, 2010, Pages 111-118

  Eidt Koch, Daniela ^a   Wagner, Thomas O F ^b   Mittendorf, Thomas ^a   Graf Von Der Schulenburg, J Matthias ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Cost analysis; Cystic fibrosis

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; COLISTIN; DORNASE ALFA; FLUTICASONE PROPIONATE PLUS SALMETEROL; ITRACONAZOLE; KREON 10000; KREON 25000; KREON 40000; MUCOLYTIC AGENT; PANCREATIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CALORIC INTAKE; CHILD; COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG COST; ENZYME REPLACEMENT; FORCED EXPIRATORY VOLUME; GERMANY; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PANCREAS INSUFFICIENCY; VITAMIN SUPPLEMENTATION;

AGE FACTORS; AMBULATORY CARE; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DRUG COSTS; HUMANS; LINEAR MODELS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS;

EID: 77649151721     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11313980-000000000-00000     Document Type: Article

References (23)

1. Griese M, Hüls G, Lindemann H. Atemwege und Lunge. In: Lindemann H, Tümmler B, Dockter G, editors. Mukoviszidose - zystische fibrose. Stuttgart: Thieme, 2004: 59-60
2. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. AmJ Respir Crit Care Med 2007; 176 (10): 957-969
3. Ballmann M, Smaczny C. CF-Manual. Hannover: Solvay Arzneimittel, 1998: chapter 34: 1-4
4. Elliott RA, Thornton J, Webb AK, et al. Comparing costs of home- versus hospital-based treatment of infections in adults in a specialist cystic fibrosis center. Int J Technol Assess Health Care 2005; 21 (4): 506-510
5. Thornton J, Elliott RA, Tully MP, et al. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros 2005; 4 (4): 239-247
6. Krauth C, Busse R, Smaczny C, et al. Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients: results of a controlled prospective study [in German]. Med Klin (Munich) 1999; 94 (10): 541-548
7. Schulenburg JM, Greiner W, Klettke U, et al. Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection: ambulatory intravenous therapy in comparison with inpatient treatment [in German]. Med Klin (Munich) 1997; 92 (10): 626-629
8. Wolter JM, Bowler SD, Nolan PJ, et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997; 10 (4): 896-900
9. Kane RE, Jennison K, Wood C, et al. Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 1988; 4 (2): 84-89
10. DIMDI - Deutsches Institut für Medizinische Dokumentation und Information, ed. Anatomisch-therapeutischechemische Klassifikation nach Tagesdosen - Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahre 2006. Köln, 2006
11. Rote Liste Service GmbH. Rote Liste - Arzneimittelverzeichnis für Deutschland. Frankfurt/Main: Rote Liste Service GmbH, 2006
12. Bundesvereinigung Deutscher Apothekerverbände (Federal Union of German Associations of Pharmacists). Berlin: ABDA-Artikeldatenstamm, 2006
13. Stern M, Sens B, Wiedemann B, et al., editors. Qualitä tssicherung Mukoviszidose - Überblick über den Gesundheitszustand der Patienten in Deutschland 2005. Berlin: MedizinischWissenschaftliche Verlagsgesellschaft, 2007
14. Krauth C, Jalilvand N, Welte T, et al. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003; 21 (14): 1001-1024
15. Ireys H, Anderson G, Shaffer T, et al. Expenditures for care of children with chronic illnesses enrolled in Washington State Medicaid Program, fiscal year 1993. Pediatrics 1997; 100: 197-204
16. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999; 19: 1159-1166
17. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999; 103: 72-75
18. Pauly MV. The economics of cystic fibrosis. In: Lloyd-Still JD, editor. Textbook of cystic fibrosis. Boston (MA): John Wright PSG Inc., 1983: 465-476
19. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992; 47: 684-689
20. Schreyögg J, Hollmeyer H, Bluemel M, et al. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006; 10: 999-1009
21. Wildhagen MF, Verheij JB, Hilderink HBM, et al. Cost of care of patients with cystic fibrosis in the Netherlands in 1990-1. Thorax 1996; 51: 298-301
22. Wildhagen MF, Verheij JB, Verzijl JG, et al. The nonhospital costs of care of patients with CF in the Netherlands: results of a questionnaire. Eur Resp J 1996; 9: 2215-2219
23. Baumann U, Stocklossa C, Greiner W. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003; 2: 84-90